Title |
Pyruvate sensitizes pancreatic tumors to hypoxia-activated prodrug TH-302
|
---|---|
Published in |
Cancer & Metabolism, January 2015
|
DOI | 10.1186/s40170-014-0026-z |
Pubmed ID | |
Authors |
Jonathan W Wojtkowiak, Heather C Cornnell, Shingo Matsumoto, Keita Saito, Yoichi Takakusagi, Prasanta Dutta, Munju Kim, Xiaomeng Zhang, Rafael Leos, Kate M Bailey, Gary Martinez, Mark C Lloyd, Craig Weber, James B Mitchell, Ronald M Lynch, Amanda F Baker, Robert A Gatenby, Katarzyna A Rejniak, Charles Hart, Murali C Krishna, Robert J Gillies |
Abstract |
Hypoxic niches in solid tumors harbor therapy-resistant cells. Hypoxia-activated prodrugs (HAPs) have been designed to overcome this resistance and, to date, have begun to show clinical efficacy. However, clinical HAPs activity could be improved. In this study, we sought to identify non-pharmacological methods to acutely exacerbate tumor hypoxia to increase TH-302 activity in pancreatic ductal adenocarcinoma (PDAC) tumor models. |
X Demographics
Geographical breakdown
Country | Count | As % |
---|---|---|
United States | 2 | 40% |
Unknown | 3 | 60% |
Demographic breakdown
Type | Count | As % |
---|---|---|
Members of the public | 3 | 60% |
Scientists | 1 | 20% |
Science communicators (journalists, bloggers, editors) | 1 | 20% |
Mendeley readers
Geographical breakdown
Country | Count | As % |
---|---|---|
United States | 3 | 4% |
Japan | 1 | 1% |
Unknown | 63 | 94% |
Demographic breakdown
Readers by professional status | Count | As % |
---|---|---|
Student > Ph. D. Student | 12 | 18% |
Researcher | 11 | 16% |
Other | 7 | 10% |
Student > Postgraduate | 6 | 9% |
Professor > Associate Professor | 6 | 9% |
Other | 11 | 16% |
Unknown | 14 | 21% |
Readers by discipline | Count | As % |
---|---|---|
Biochemistry, Genetics and Molecular Biology | 13 | 19% |
Medicine and Dentistry | 12 | 18% |
Agricultural and Biological Sciences | 10 | 15% |
Pharmacology, Toxicology and Pharmaceutical Science | 2 | 3% |
Engineering | 2 | 3% |
Other | 8 | 12% |
Unknown | 20 | 30% |